Indomethacin Prophylaxis Is Associated with Reduced Risk of Intraventricular Hemorrhage in Extremely Preterm Infants Born in the Context of Amniotic Infection Syndrome.


Journal

Neonatology
ISSN: 1661-7819
Titre abrégé: Neonatology
Pays: Switzerland
ID NLM: 101286577

Informations de publication

Date de publication:
2023
Historique:
received: 08 08 2022
accepted: 06 01 2023
medline: 13 7 2023
pubmed: 1 6 2023
entrez: 31 5 2023
Statut: ppublish

Résumé

Amniotic infection syndrome (AIS) with perinatal inflammation may increase the susceptibility to intraventricular hemorrhage (IVH) in preterm infants. Given its anti-inflammatory and ductus arteriosus constricting capacities, we hypothesized that prophylactic administration of indomethacin reduces the incidence, severity, and consequences of IVH in the context of perinatal inflammation. We evaluated data of infants born between 2009 and 2020 of 22 + 0-25+6 weeks of gestation from 68 German Neonatal Network centers. The effect of indomethacin prophylaxis on outcomes was analyzed in univariate analyses and multivariate regression models including a subgroup of infants with available data on 5-year follow-up. 4760 infants were included with a median gestational age of 24.6 SSW [interquartile range (IQR) 24.1w-25.2w] and a birth weight of 640 g [IQR 550-750 g]. 1767/4760 (37.1%) preterm infants were born in the context of AIS and 527/4760 (11.1%) received indomethacin prophylaxis. AIS infants receiving prophylactic indomethacin had lower rates of IVH (32.7% vs. 36.9%, p = 0.04), IVH III/IV (9.7% vs. 16.0%, p = 0.02) and the combined outcome of severe IVH or death (15.9% vs. 23.2%, p = 0.01) as compared to infants without prophylaxis. Multivariate logistic regression analyses confirmed our observations. In a subgroup analysis of 730 preterm infants at 5 years of age, we did not find any correlation between prophylactic indomethacin and intelligence quotient <70 or cerebral palsy. Our observational data demonstrate that prophylactic indomethacin is associated with a reduced risk of IVH in the highly vulnerable subgroup of preterm infants <26 weeks of gestation born from AIS.

Sections du résumé

BACKGROUND
Amniotic infection syndrome (AIS) with perinatal inflammation may increase the susceptibility to intraventricular hemorrhage (IVH) in preterm infants. Given its anti-inflammatory and ductus arteriosus constricting capacities, we hypothesized that prophylactic administration of indomethacin reduces the incidence, severity, and consequences of IVH in the context of perinatal inflammation.
METHODS
We evaluated data of infants born between 2009 and 2020 of 22 + 0-25+6 weeks of gestation from 68 German Neonatal Network centers. The effect of indomethacin prophylaxis on outcomes was analyzed in univariate analyses and multivariate regression models including a subgroup of infants with available data on 5-year follow-up.
RESULTS
4760 infants were included with a median gestational age of 24.6 SSW [interquartile range (IQR) 24.1w-25.2w] and a birth weight of 640 g [IQR 550-750 g]. 1767/4760 (37.1%) preterm infants were born in the context of AIS and 527/4760 (11.1%) received indomethacin prophylaxis. AIS infants receiving prophylactic indomethacin had lower rates of IVH (32.7% vs. 36.9%, p = 0.04), IVH III/IV (9.7% vs. 16.0%, p = 0.02) and the combined outcome of severe IVH or death (15.9% vs. 23.2%, p = 0.01) as compared to infants without prophylaxis. Multivariate logistic regression analyses confirmed our observations. In a subgroup analysis of 730 preterm infants at 5 years of age, we did not find any correlation between prophylactic indomethacin and intelligence quotient <70 or cerebral palsy.
CONCLUSIONS
Our observational data demonstrate that prophylactic indomethacin is associated with a reduced risk of IVH in the highly vulnerable subgroup of preterm infants <26 weeks of gestation born from AIS.

Identifiants

pubmed: 37257433
pii: 000529140
doi: 10.1159/000529140
doi:

Substances chimiques

Indomethacin XXE1CET956

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

334-343

Informations de copyright

© 2023 S. Karger AG, Basel.

Auteurs

Kathrin Hanke (K)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Ingmar Fortmann (I)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Alexander Humberg (A)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.
Department of General Pediatrics, University Hospital Münster, Münster, Germany.

Kirstin Faust (K)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Angela Kribs (A)

Department of Pediatrics, University of Cologne, Cologne, Germany.

Sebastian Prager (S)

Department of Pediatrics I, University of Duisburg-Essen, Essen, Germany.
Center of Translational Neuro- and Behavioral Sciences C-TNBS, University of Duisburg-Essen, Essen, Germany.

Ursula Felderhoff-Müser (U)

Department of Pediatrics I, University of Duisburg-Essen, Essen, Germany.
Center of Translational Neuro- and Behavioral Sciences C-TNBS, University of Duisburg-Essen, Essen, Germany.

Marcus Krüger (M)

Department of Neonatology, Munich Clinic, Munich, Germany.

Matthias Heckmann (M)

Department of Neonatology and Pediatric Intensive Care, University Medicine Greifswald, Greifswald, Germany.

Anja Jäger (A)

Department of Neonatology, Mönchengladbach, Mönchengladbach, Germany.

Oliver Andres (O)

Department of Pediatrics, University of Würzburg, Würzburg, Germany.

Juliane Spiegler (J)

Department of Pediatrics, University of Würzburg, Würzburg, Germany.

Christoph Härtel (C)

Department of Pediatrics, University of Würzburg, Würzburg, Germany.

Egbert Herting (E)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Wolfgang Göpel (W)

Department of Pediatrics, University of Lübeck, Lübeck, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH